BioInsights - Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture - spotlight

CELL & GENE THERAPY INSIGHTS

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture

Jan Thirkettle
Guest Editor:
Jan Thirkettle, Chief Development Officer at Freeline Therapeutics Limited
September 2020

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture
Download PDF

Foreword


Expert Insight


Innovator Insight


Commentary


Interview


Podcast


Expert Roundtable Video


Expert Roundtable


FastFacts


Webinars